Status:
RECRUITING
A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany
Lead Sponsor:
Blueprint Medicines Corporation
Conditions:
Indolent Systemic Mastocytosis
Eligibility:
All Genders
18+ years
Brief Summary
This is a non-interventional study assessing the effectiveness of avapritinib (BLU-285) in the management of ISM in real-world settings in Germany. The study also seeks to address the existing data ga...
Eligibility Criteria
Inclusion Criteria:
- Participants is starting avapritinib treatment at the HCP's discretion as part of their routine care (for ISM with moderate to severe symptoms inadequately controlled with symptomatic treatment) and in accordance with approved SmPC.
Exclusion Criteria:
- Participant with a potential increased risk for intracranial hemorrhage including those with a history of vascular aneurysm, intracranial hemorrhage, cerebrovascular accident within the prior year, or severe thrombocytopenia.
- Participant who has previously taken avapritinib as a commercial drug or as part of a clinical study.
Key Trial Info
Start Date :
December 9 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2028
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT07255638
Start Date
December 9 2025
End Date
December 1 2028
Last Update
February 10 2026
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Charité Universitätmedizin Berlin, Klinik für Dermatologie, Venerologie und Allergologie
Berlin, Germany, 10117
2
Universitätsklinikum Carl Gustav Carus Dresden Klinik und Poliklinik für Dermatologie
Dresden, Germany, 01307
3
University Medical Center Goettingen - Georg August University of Goettingen
Göttingen, Germany, 37075
4
Universitats-Hautklinik Tubingen, Studienzentrum lmmundermatologie
Tübingen, Germany, 72076